Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers - General NASDAQ
$130.28
$-3.36 (-2.51%)
Open: $131.54 | High: $132.33 | Low: $129.28 | Prev Close: Prev Close: $133.64
Market Cap: $161.71B
Volume: 5.5M | Avg: 6.7M
Last updated: April 24, 2026 at 08:02 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 592
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 15.99 |
| P/B Ratio | 7.15 |
| P/S Ratio | 5.49 |
| EPS | $8.15 |
| Beta | 0.40 |
| Shares Outstanding | 1.24B |
| 52-Week High | $157.29 |
| 52-Week Low | $93.37 |
| SMA 50 | $143.19 |
| SMA 200 | $126.25 |
| Dividend Yield | 2.45% |
| Annual Dividend | $3.19 |
| Next Earnings | May 07, 2026 08:00 PM ET |
Financial Ratios
| Gross Margin | 80.8% |
| Operating Margin | 37.4% |
| Net Margin | 28.9% |
| ROE | 41.0% |
| ROA | 14.4% |
| Debt/Equity | 1.09 |
| Current Ratio | 1.68 |
| Quick Ratio | 1.31 |
Balance Sheet
| Total Assets | $59.02B |
| Total Liabilities | $36.41B |
| Total Equity | $22.62B |
|
|
|
| Cash | $7.56B |
| Total Debt | $24.59B |
| Net Debt | $17.03B |
Income Statement
| Revenue | $29.44B |
| Gross Profit | $25.52B |
| Operating Income | $11.82B |
| Net Income | $8.51B |
|
|
|
| EBITDA | $10.82B |
| Revenue/Share | $23.71 |
Cash Flow
| Operating CF | $10.02B |
| CapEx | $563.00M |
| Free Cash Flow | $9.46B |
|
|
|
| Book Value/Share | $18.21 |
| Tangible Book/Share | $-2.15 |
| Equity/Share | $18.21 |
Technical Indicators
| RSI (14) | 26.29 Oversold |
| MACD |
-2.33
Signal: -1.61
|
| Volatility | 22.30% |
| Trading Signal | Oversold |
Performance & Returns
| 1 Year | +15.05% |
| Sharpe Ratio | 0.59 Fair |
| Volatility (Ann.) | 26.19% Moderate |
| GILD (1Y) | +15.05% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +0.64% |
Sector Comparison (Healthcare)
| Metric | GILD | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 15.99 | 26.45 | 24% |
| P/B Ratio | 7.15 | -21.16 | 80% |
| ROE (%) | 41.01% | -10.73% | 90% |
| Net Margin (%) | 28.90% | 9.04% | 92% |
| Stock Score | 592 | 548.0 | 70% |
| 1Y Return (%) | +15.05 % | +4.93 % | 71% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | $130.28 | $133.36 | $135.43 | $137.34 | $142.85 | $126.38 | 26.29 | -2.33 | 22.30% | 839262 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the GILD stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| GILD | Brindle & Bay Financial Advisors LLC Purchases Shares of 6,042 Gilead Sciences, Inc. $GILD | Neutral | defenseworld.net | Read More |
| GILD | AEGON ASSET MANAGEMENT UK Plc Reduces Holdings in Gilead Sciences, Inc. $GILD | Neutral | defenseworld.net | Read More |
| GILD | Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD | Neutral | defenseworld.net | Read More |
| GILD | Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts | Positive | zacks.com | Read More |
| GILD | Atwood & Palmer Inc. Has $42.94 Million Holdings in Gilead Sciences, Inc. $GILD | Neutral | defenseworld.net | Read More |
Recent Insider Trading
No recent insider trading data available for GILD
Company Information
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
| CEO | Daniel O'Day |
| Employees | 17600 |
| Country | US |
| IPO Date | 1992-01-22 |
| Exchange | NASDAQ |
| Website | https://www.gilead.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Similar Stocks (Healthcare - Drug Manufacturers - General)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category